294 related articles for article (PubMed ID: 18083549)
41. The immunogenicity of the virus-like particles derived from the VP2 protein of porcine parvovirus.
Hua T; Zhang D; Tang B; Chang C; Liu G; Zhang X
Vet Microbiol; 2020 Sep; 248():108795. PubMed ID: 32827923
[TBL] [Abstract][Full Text] [Related]
42. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
[TBL] [Abstract][Full Text] [Related]
43. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
[TBL] [Abstract][Full Text] [Related]
44. Stability of virus-like particles of red-spotted grouper nervous necrosis virus in the aqueous state, and the vaccine potential of lyophilized particles.
Lan NT; Kim HJ; Han HJ; Lee DC; Kang BK; Han SY; Moon H; Kim HJ
Biologicals; 2018 Jan; 51():25-31. PubMed ID: 29174141
[TBL] [Abstract][Full Text] [Related]
45. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
46. Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design.
Joshi H; Lewis K; Singharoy A; Ortoleva PJ
Vaccine; 2013 Oct; 31(42):4841-7. PubMed ID: 23933338
[TBL] [Abstract][Full Text] [Related]
47. Zika virus-like particles (VLPs): Stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform.
Alvim RGF; Itabaiana I; Castilho LR
Vaccine; 2019 Nov; 37(47):6970-6977. PubMed ID: 31164305
[TBL] [Abstract][Full Text] [Related]
48. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
49. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
50. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
McGinnes Cullen L; Schmidt MR; Morrison TG
J Virol; 2019 May; 93(9):. PubMed ID: 30760576
[TBL] [Abstract][Full Text] [Related]
51. Virus-like particles as vaccine.
Chroboczek J; Szurgot I; Szolajska E
Acta Biochim Pol; 2014; 61(3):531-9. PubMed ID: 25273564
[TBL] [Abstract][Full Text] [Related]
52. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine.
Madore HP; Estes MK; Zarley CD; Hu B; Parsons S; Digravio D; Greiner S; Smith R; Jiang B; Corsaro B; Barniak V; Crawford S; Conner ME
Vaccine; 1999 May; 17(19):2461-71. PubMed ID: 10392629
[TBL] [Abstract][Full Text] [Related]
53. Detection of the Assembly and Disassembly of PCV2b Virus-Like Particles Using Fluorescence Spectroscopy Analysis.
Fang M; Diao W; Dong B; Wei H; Liu J; Hua L; Zhang M; Guo S; Xiao Y; Yu Y; Wang L; Wan M
Intervirology; 2015; 58(5):318-23. PubMed ID: 26783743
[TBL] [Abstract][Full Text] [Related]
54. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
[TBL] [Abstract][Full Text] [Related]
55. Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horse.
Hainisch EK; Abel-Reichwald H; Shafti-Keramat S; Pratscher B; Corteggio A; Borzacchiello G; Wetzig M; Jindra C; Tichy A; Kirnbauer R; Brandt S
J Gen Virol; 2017 Feb; 98(2):230-241. PubMed ID: 28284277
[TBL] [Abstract][Full Text] [Related]
56. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.
Swenson DL; Warfield KL; Larsen T; Alves DA; Coberley SS; Bavari S
Expert Rev Vaccines; 2008 May; 7(4):417-29. PubMed ID: 18444889
[TBL] [Abstract][Full Text] [Related]
57. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
[TBL] [Abstract][Full Text] [Related]
58. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Viscidi R; Harro CD; Kemp TJ; García-Piñeres AJ; Trivett M; Demuth F; Lowy DR; Schiller JT; Berzofsky JA; Hildesheim A
Virology; 2006 Sep; 353(2):451-62. PubMed ID: 16863657
[TBL] [Abstract][Full Text] [Related]
59. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
[TBL] [Abstract][Full Text] [Related]
60. Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge.
Bhat SA; Saravanan P; Hosamani M; Basagoudanavar SH; Sreenivasa BP; Tamilselvan RP; Venkataramanan R
Res Vet Sci; 2013 Dec; 95(3):1217-23. PubMed ID: 23969204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
